MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective study

医学 神经母细胞瘤RAS病毒癌基因同源物 临床试验 回顾性队列研究 黑色素瘤 内科学 置信区间 肿瘤科 随机对照试验 疾病 挽救疗法 外科 癌症 化疗 癌症研究 结直肠癌 克拉斯
作者
Martin Salzmann,Johannes Pawlowski,Carmen Loquai,David Ali Rafei-Shamsabadi,Frank Meiß,Selma Ugurel,Dirk Schadendorf,Friedegund Elke Meier,Alexander Enk,Jessica C. Hassel
出处
期刊:European Journal of Cancer [Elsevier BV]
卷期号:166: 24-32 被引量:26
标识
DOI:10.1016/j.ejca.2022.02.008
摘要

MEK inhibitors (MEKi) have shown clinical efficacy for NRAS-mutated, metastasized melanoma in randomised controlled trials, yet their clinical use is currently restricted to advanced, pre-treated patients, which is a different situation compared to previous trials. Data on their efficacy in the current real-world use are scarce.In this retrospective, multi-centre study, we evaluated the clinical course of disease of patients treated with MEKi with at least one previous treatment line in five German cancer centres.Thirty-three patients were included, 19 males (58%) and 14 females (42%), with a median age of 64 years. Ninety-one percent of patients were pre-treated with immune checkpoint inhibitors, 90% of patients had elevated serum lactate dehydrogenase (LDH) levels at treatment initiation, 33% suffered from cerebral metastases and 30% had an Eastern Cooperative Oncology Group performance status of 2 or higher. The response rate was 18.2%; the disease control rate was 48.5%. Median progression-free survival was 2.8 months (95% confidence interval (CI): 1.6-3.9 months), and median overall survival was 7.1 months (95% CI: 5.8-8.3 months). In subgroup analysis, clinical efficacy was similar also in patients with high LDH levels and cerebral metastases, and there was a better outcome in males and in patients treated with trametinib vs. other MEKi, which may be based on selection bias. Overall, the clinical efficacy was similar compared to previous clinical trials in earlier treatment lines.MEKi fulfil the need for an in-between treatment to stabilise the course of disease in advanced NRAS-mutated melanoma, but expectations regarding ongoing tumour response should be tempered.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
情怀的应助被科研通管家采纳,获得10
刚刚
刚刚
IDCY的应助被科研通管家采纳,获得30
刚刚
研友_VZG7GZ的应助被科研通管家采纳,获得10
刚刚
Jasper的应助被科研通管家采纳,获得10
刚刚
dlindl发布了新的文献求助10
刚刚
1秒前
汉堡包的应助被科研通管家采纳,获得10
1秒前
开心完成签到,获得积分10
1秒前
英姑的应助被科研通管家采纳,获得10
1秒前
传奇3的应助被科研通管家采纳,获得10
1秒前
慕青的应助被科研通管家采纳,获得10
1秒前
1秒前
看不懂英语完成签到,获得积分10
2秒前
wanci的应助被科研通管家采纳,获得10
2秒前
小马甲的应助被科研通管家采纳,获得10
2秒前
梵高晚风发布了新的文献求助10
2秒前
Orange的应助被科研通管家采纳,获得10
2秒前
2秒前
英俊的铭的应助被科研通管家采纳,获得10
2秒前
Lion完成签到,获得积分10
2秒前
研友_VZG7GZ的应助被科研通管家采纳,获得10
2秒前
明明发布了新的文献求助10
2秒前
脑洞疼的应助被科研通管家采纳,获得10
2秒前
思源的应助被科研通管家采纳,获得10
2秒前
CodeCraft的应助被科研通管家采纳,获得10
3秒前
3秒前
酷波er的应助被科研通管家采纳,获得10
3秒前
fantasy的应助被科研通管家采纳,获得10
3秒前
上官若男的应助被科研通管家采纳,获得10
3秒前
wang发布了新的文献求助10
3秒前
wanci的应助被科研通管家采纳,获得10
3秒前
李健的应助被科研通管家采纳,获得10
3秒前
Ava的应助被科研通管家采纳,获得10
3秒前
3秒前
在水一方的应助被科研通管家采纳,获得10
3秒前
4秒前
4秒前
怎么忘了发布了新的文献求助10
4秒前
Meteor完成签到,获得积分10
4秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8176174
求助须知:如何正确求助?哪些是违规求助? 9567656
关于积分的说明 21793895
捐赠科研通 7770887
什么是DOI,文献DOI怎么找? 3431991
关于科研通互助平台的介绍 2556313
邀请新用户注册赠送积分活动 2477540